Date |
Title |
|
IMMUNOMEDICS ANNOUNCES FISCAL 2010 RESULTS
|
|
IMMUNOMEDICS AND GE HEALTHCARE IN RESEARCH COLLABORATION
|
|
IMMUNOMEDICS AWARDED ADDITIONAL U.S. PATENT FOR INTERNALIZING ANTI-CD74 ANTIBODIES AND METHODS OF USE
|
|
EPRATUZUMAB DATA FROM PHASE IIB EMBLEM™ STUDY PRESENTED AT 9TH INTERNATIONAL CONGRESS ON SYSTEMIC LUPUS ERYTHEMATOSIS
|
|
RESULTS FROM RANDOMIZED STUDY OF EPRATUZUMAB IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS PRESENTED AT EUROPEAN RHEUMATOLOGY CONGRESS
|
|
NEW DATA FROM EMBLEM™ STUDY SHOW PIPELINE DRUG EPRATUZUMAB PROVIDED SIGNIFICANT EFFICACY FOR PATIENTS SUFFERING FROM MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS
|
|
IMMUNOMEDICS DOSES FIRST PATIENT IN PHASE I/II STUDY OF MILATUZUMAB-DOXORUBICIN CONJUGATE FOR MULTIPLE MYELOMA THERAPY
|
|
IMMUNOMEDICS ANNOUNCES PRECLINICAL RESULTS OF PRETARGETED IMAGING AND THERAPY OF CANCER
|
|
IMMUNOMEDICS PRESENTS NEW ANTIBODY FOR PRETARGETING EPITHELIAL CANCERS AT MEDICAL CONFERENCE
|
|
IMMUNOMEDICS REPORTS FIRST CLINICAL EXPERIENCE WITH NEW GENERATION OF BISPECIFIC ANTIBODY |
|
IMMUNOMEDICS REPORTS UPDATED RESULTS OF TARGETED THERAPY FOR ADVANCED PANCREATIC CANCER |
|
IMMUNOMEDICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES |
|
IMMUNOMEDICS TO REPORT PROGRESS ON CANCER IMAGING AND THERAPY IN 9 PRESENTATIONS AT THE SOCIETY OF NUCLEAR MEDICINE’S 57th ANNUAL MEETING |
|
IMMUNOMEDICS RECEIVES SECOND MILESTONE PAYMENT FROM NYCOMED |
|
RESULTS FROM RANDOMIZED STUDY OF EPRATUZUMAB IN PATIENTS WITH LUPUS TO BE PRESENTED AT EUROPEAN RHEUMATOLOGY CONGRESS |
|
IMMUNOMEDICS ANNOUNCES THIRD QUARTER FISCAL 2010 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS |
|
IMMUNOMEDICS DEVELOPS POTENT IMMUNOTOXINS AGAINST SOLID AND LIQUID TUMORS |
|
IMMUNOMEDICS REPORTS NEW BLOOD TEST FOR DETECTING EARLY STAGE PANCREATIC CANCER CORRELATES WITH RESPONSE TO CLIVATUZUMAB TETRAXETAN TREATMENT |
|
IMMUNOMEDICS REPORTS PROGRESS ON ANTIBODY-DRUG CONJUGATE DEVELOPMENT AT CANCER MEETING |
|
IMMUNOMEDICS DEVELOPS NOVEL IMMUNOCONJUGATE FOR TARGETED DELIVERY OF siRNAs TO SOLID CANCERS |
|
IMMUNOMEDICS TO REPORT ON POTENTIAL CANCER THERAPY PRODUCTS IN 8 PRESENTATIONS AT 101ST ANNUAL AACR MEETING |
|
IMMUNOMEDICS TO PRESENT AT BARCLAYS CAPITAL 2010 GLOBAL HEALTHCARE CONFERENCE |
|
IMMUNOMEDICS AWARDED PATENTS FOR ANTIBODY FOR PEGYLATION AND PRETARGETING CONSTRUCTS |
|
IMMUNOMEDICS TO PARTICIPATE IN UPCOMING CONFERENCES |
|
IMMUNOMEDICS AWARDED PATENT FOR ANTIBODY THERAPY |
|
IMMUNOMEDICS APPOINTS KENNETH J ZUERBLIS TO BOARD OF DIRECTORS |
|
IMMUNOMEDICS ANNOUNCES SECOND QUARTER FISCAL 2010 RESULTS AND CLINICAL PROGRAM DEVELOPMENTS |
|
NEW TARGETED THERAPY FOR PANCREATIC CANCER PRESENTED AT CANCER CONFERENCE |
|
NEW BLOOD TEST FOR DETECTING EARLY STAGE PANCREATIC CANCER PRESENTED AT CANCER CONFERENCE |
|
IMMUNOMEDICS RECEIVES first MILESTONE PAYMENT FROM NYCOMED |
|
POTENTIAL LUPUS DRUG GAINS US PATENT |
|
IMMUNOMEDICS TO PRESENT AT 28th ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE |
